⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S2 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor

Suzanne George Michael C. Heinrich Neeta Somaiah Peter Oppelt Robert McLeod Satoshi Nishioka Madan G. Kundu Xiaozhong Qian Prasanna Kumar Abderrahmane Laadem Yvonne Lau Brittany P. Tran Maura Fallon Ololade Dosunmu Julia Shi Yoichi Naito

View at Publisher

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplementary Figure S2. DXd immunohistochemistry in a patient treated with 6.4 mg/kg DS-6157a (A) pre-treatment and (B) on treatment (Cycle 2, Day 10)

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

George et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522687 https://doi.org/10.1158/1078-0432.27032515

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor2024
2Supplementary Figure S1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor2024
3Supplementary Figure S1 from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor2024
4Data from A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor2024
5Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors2024

Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors2024
Supplementary Figure S2 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas2025
Supplementary Figure S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer2025